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Hematopoietic Stem Cell Transplantation
Michelle B. Mahler,1 Ying Taur,2 Raymond Jean,1 Nancy A. Kernan,1
Susan E. Prockop,1 Trudy N. Small1Given the high morbidity and mortality associated with meningococcal disease, in 2007 the Advisory
Committee of Immunization Practices recommended immunization of all children ages 11-18 with a pro-
tein-conjugated meningococcal vaccine. There are limited data on the immunogenicity of this vaccine after
allogeneic hematopoietic stem cell transplantation (allo-HCT). Since 2007, we have immunized 48 patients
with the MCV4 vaccine. Two vaccinated patients who lacked follow-up titers were excluded from this anal-
ysis. Stem cells were derived from an HLA-identical sibling (n 5 17) or an alternative donor (n 5 29). The
median time to vaccination was 2.34 years after allo-HCT. Only 7 patients responded to all 4 serogroups, and
16 patients responded to none of the serogroups. The response to serogroups A, C, Y, andW-135 was 52%,
30%, 46%, and 33%, respectively. The ability to respond to 2 or more serogroups was not affected by age,
diagnosis, time to vaccination, or history of graft-versus-host disease. Receipt of a T cell–depleted graft
was associated with a poorer response (P5 .044). Eight of 16 patients who received a second MCV4 vacci-
nation responded to all 4 serogroups. This retrospective study suggests that response to a single MCV4
vaccination is poor after allo-HCT. Administration of a 2-dose series, as currently recommended for patients
with asplenia, complement deficiency, and HIV infection, should be evaluated in this patient population.
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An estimated 1.2million cases of invasivemeningo-
coccal disease occur worldwide each year, causing
135,000 deaths annually [1-3]. Each year in the
United States, approximately 1000-3000 cases are
reported [2]. Bacteremia, meningitis, and pneumonia
occur in approximately 75%, 50%, and 15%of infected
patients, respectively. Fulminant sepsis occurs in 5%-
20% of patients with bloodstream infections. Despite
rapid institution of appropriate antibiotics, 10%-14%
of infected patients die. Of those who survive, up
to 20% experience significant morbidity, including1Departments of Pediatrics; and 2Infectious Disease,
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6/j.bbmt.2011.07.027vasculitis, suppurative arthritis, myocarditis, and per-
manent neurologic sequelae, such as deafness [1-4].
In the United States, meningococcal disease
occurs in 2 peaks, one in infancy and the other in
adolescents and young adults [1-4]. In infants, 50% of
meningococcal disease is due to serogroup B, which
shares homology with fetal neural tissue and is poorly
immunogenic [5]. Although several groups areworking
on vaccines containing this serogroup [6], no currently
licensed vaccine in the United States contains this
antigen [3,4,6]. In individuals .11 years old, 75% of
meningococcal disease is caused by serogroups C, Y,
and W-135, each of which is included in the currently
licensed meningococcal vaccines [3,4,6].
Before 2005, Menomune-A/C/Y/W-135 (Sanofi
Pasteur, Swiftwater, PA), licensed in 1981, was the
only meningococcal vaccine available in the United
States [3]. This pure polysaccharide vaccine, although
immunogenic in older children and adults, does not
induce long-term memory or an anamnestic response
on antigenic reexposure [3]. In 2005, the Food and
Drug Administration licensed the protein conjugated
meningococcal vaccine, MCV4 (Menactra; Sanofi
Pasteur), which contains 4 mg each of meningococcal
Table 1. Patient and Transplant Characteristics
Sex, male/female 27/19
Age at HCT, years, median (range) 13.9 (6-23)
Age at vaccination, years, median (range) 14.7 (9.6-25.4)
Diagnosis, n
Malignancy/bone marrow failure 40
Acute leukemia 32
Myelodysplastic syndrome/aplastic anemia 5 (3/2)
Chronic myelogenous leukemia/
myeloproliferative disorder
2 (1/1)
Ewing sarcoma 1
Nonmalignant disease 6
Hemoglobinopathy 4
Combined immunodeficiency disease 1
Hereditary lymphohistiocytosis 1
Time from HCT to vaccine, years, median
(range)
2.34 (0.6-5.2)
Donor, n (%)
HLA-identical sibling 17 (37)
HLA-mismatched related 6 (13)
Unrelated 23 (50)
HCT type, n (%)
T cell depleted 26 (57)
HLA-identical sibling 4
HLA-mismatched related 6
Unrelated 16
T cell replete 20 (43)
Unmodified HLA-identical sibling 13
Unmodified unrelated 2
Unmodified double cord blood 5
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to approximately 48 mg of diphtheria toxoid protein
carrier. Compared with the pure polysaccharide
meningococcal vaccine, the conjugated vaccine is
more immunogenic in young children, elicits a T cell–
dependent B cell response, decreases nasal coloniza-
tion, results in higher seroconversion rate, and
provides more durable seroprotection [3-5].
Over the past decade, disease-free survival after
hematopoietic stem cell transplantation (HCT) has
continued to improve, resulting in an increasing num-
ber of patients entering college and the work force and
traveling abroad [7]. To date, only 1 study has evalu-
ated the immunogenicity of the polysaccharide menin-
gococcal vaccine in allogeneic HCT (allo-HCT)
survivors [8], and no study has evaluated the immuno-
genicity of a quadrivalent protein-conjugated menin-
gococcal vaccine.
To determine the safety and immunogenicity of
this vaccine in allo-HCT, this retrospective study ana-
lyzed the response and adverse side effects in 46 pa-
tients who received this vaccine at our center between
2007 and 2010. The effects of transplant type, patient
age, stem cell and donor type, use of T cell depletion,
and history of previous acute or chronic graft-versus-
host disease (GVHD) on seroconversionwere assessed.PATIENTS AND METHODS
A waiver of authorization to conduct this retro-
spective study was approved by the Memorial Sloan-Kettering Cancer Center’s Institutional Review Board.
Routine immunization of patients with MCV4 was
initiated at Memorial Sloan-Kettering Cancer Center
in 2007 in accordance with Advisory Committee on
Immunization Practices (ACIP) guidelines published
that year. These guidelines recommended immuniza-
tion of all children ages 11-18, splenectomized individ-
uals of any age, and individuals age.18 enrolled in the
military, living in a college dormitory, traveling to
a high-risk area, or working as a healthcare profes-
sional [9]. The medical records of all patients who
remained disease-free for at least 6 months after allo-
HCT performed at this center between January 1,
2004, and December 31, 2009, were reviewed for
immunization against meningococcus. Dates of vacci-
nation and prevaccine and postvaccine titers were
obtained from a prospectively maintained database
and confirmed by retrospective chart review. Only
patients who underwent HCT since 2004 were in-
cluded, to limit the maximum time between HCT
and vaccination to 6 years.
Antibody Response
Serum IgG antibodies recognizing the 4 Neisseria
meningitidis serogroups included in MCV4 were
assessed by Focus Technologies (Cypress, CA) using
a multianalyte immunodetection procedure, based on
the Luminex flow cytometric system [10]. The
threshold for response against serogroups A, C, Y,
and W-135 was defined as a specific IgG level of
.4, 5, 4, and 3 mg/mL, respectively. For patients
with positive titers before vaccination, response was
defined as a 3-fold increase in titer. Patients who re-
sponded to all 4 serogroups were defined as having
a full response. A good partial response was defined
as the development of protective titers against at least
2 serogroups. All patients were evaluated at our cen-
ter before and after vaccination, including assessment
of acute and chronic GVHD using established crite-
ria [11,12].
Patient and Transplant Characteristics
Forty-eight patients (median age at vaccination,
14.7 years; range, 9.6-25.4 years) received an initial
MCV4 vaccine between January 1, 2007, and Decem-
ber 31, 2010. Two recipients of a T cell–depleted
transplant derived from an unrelated (n 5 1) or
HLA-identical sibling donor (n 5 1) were not evalu-
able for response because of a lack of follow-up titers.
The remaining 46 patients form the basis of this study.
Patient and donor characteristics are presented in
Table 1. All patients received a myeloablative condi-
tioning regimen that included hyperfractionated total
body irradiation in 29 patients.
Stem cells for the 46 patients were derived from
an HLA-identical sibling in 37% of the cases, an
Table 2. Response to 2 or More MCV4 Serogroups
Characteristic
Univariate
Odds Ratio
95% Confidence
Interval P Value
Age >10 years at HCT 0.72 0.21-2.48 .604
Male sex (versus female) 1.03 0.32-3.34 .958
T cell depletion 0.29 0.08-0.97 .044
HLA-identical sibling
(versus alternative donor)
3.00 0.86-10.43 .084
Time from HCT to
MCV4 vaccination
0.5-1 year 1.00
1-2 years 0.77 0.09-6.98 .822
>2 years 1.00 0.12-8.21 1.000
History of chronic GVHD 1.77 0.47-6.72 .399
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related donor in 50%. Fifty-seven percent of patients
(26 of 46) received a T cell–depleted transplant from
an unrelated (n 5 16), an HLA-mismatched related
(n 5 6), or an HLA-identical sibling (n 5 4) donor.
In 7 patients, T cells were depleted from bone marrow
by soybean agglutination followed by sheep red blood
cells [13]. In 19 patients, granulocyte colony-
stimulating factor–mobilized peripheral blood stem
cells underwent positive selection for CD341 stem
cells, followed by T cell depletion by rosetting with
sheep erythrocytes [14]. The remaining 20 patients re-
ceived an unmodified transplant from an HLA-
identical sibling donor (n 5 13) or unrelated donor
(n 5 7). The source of this unmodified graft was dou-
ble cord blood (n 5 5), bone marrow (n 513), or pe-
ripheral blood (n 5 2). Six of the 46 patients
evaluable for response received posttransplantation
rituximab for the prevention (n 5 5) or treatment
(n 5 1) of Epstein-Barr virus lymphoproliferative
disorder.Statistical Analysis
Frequency distributions of characteristics of pa-
tients who responded to the meningococcal vaccine
and the study cohort were summarized. Logistic
regression was used to identify clinical variables associ-
ated with a good partial vaccine response (ie, response
to at least 2 serotypes). The variables included age, sex,
T cell depletion, matched related transplant (versus
other), time to first vaccination, and history of
GVHD. Univariate analysis was performed. To assess
for potential confounding effects, predictors with
a univariate P value of \.25 were incorporated into
a multivariate model. All analyses were performed us-
ing Stata version 10 (StataCorp, College Station, TX).RESULTS
Before immunization, 2 patients had a protective
titer against serogroup A. These were the only patientswho were seropositive for any serogroup before vacci-
nation. The median time to initiation of vaccination
was 2.34 years (range, 0.6-5.2 years) post-HCT. The
median time to vaccination was 2.0 years (range,
0.6-5.0 years) in recipients of a T cell–depleted HCT
and 2.6 years (range, 0.8-5.2 years) in recipients of
a T cell–replete graft (P 5 .36). In the 6 patients who
received post-HCT rituximab, the median time from
HCT to vaccination was 2.4 years. The median time
from the last dose of rituximab to initial MCV4 vacci-
nation was 25 months (range, 0.2-37.2 months), with 5
of 6 patients receiving their first vaccine more than
20 months after rituximab treatment.
The median time to measurement of antibody
levels after the initial MCV4 vaccine was 113 days.
Sixteen patients failed to respond to any serogroup
after immunization, including all 6 patients who
received post-HCT rituximab. Of the remaining 30
patients, response to 1, 2, 3, or 4 serogroups was ob-
served in 8, 7, 8, and 7 patients, respectively. The
threshold for response against serogroups A, C, Y,
and W-135 was reached in 56%, 31%, 45%, and
36% of patients, respectively. Logistic regression anal-
ysis demonstrated that the ability to respond to at least
2 serogroups was not significantly affected by age at
HCT, sex, time from HCT, or underlying diagnosis.
Only receipt of a T cell–depleted HCT was associated
with a trend toward poorer response to 2 or more
serogroups (P 5 .044) (Table 2). In terms of response
to an individual serogroup, response to serogroup C
was significantly poorer in patients who received
a T cell–depleted transplant and/or stem cells
derived from an unrelated or HLA-mismatched (alter-
native) donor (Table 3). Our analysis detected no sig-
nificant univariate predictors for serogroups A, Y, and
W-135, and results from multivariate analysis of over-
all response and serogroup C were similar to those of
the univariate analysis but with decreased statistical
power (data not shown).
To date, 16 patients have received a secondMCV4
vaccine afterT cell–depletedHCT(n59) orTcell–re-
plete HCT (n 5 7). The second vaccine was adminis-
tered at a median of 8.9 months (range, 1.6-28.4
months) after the first vaccine due to complete lack of
response (n 5 8) or response to only 1 serogroup
(n 5 5) or 2 serogroups (n 5 3). Stem cells for
the 16 patients were derived from an HLA-identical
sibling (n 5 4), an HLA-mismatched related (n 5 3),
or an unrelated volunteer donor (n5 9). After a second
MCV4 vaccination, 8 of 16 patients responded to all
4 serogroups, 5 patients responded to 3 serogroups,
and 1 patient responded to 2 serogroups. The only 2
patients who failed to respond to any serogroup after
a second MCV4 received their second vaccine 21.6
and 28.8 after their last dose of rituximab. The thresh-
old for response against serogroupsA,C,Y, andW-135
was reached in 81% (13 of 16), 63% (10 of 16), 88% (14
Table 3. Logistic Regression: Serogroup C Response
Characteristic
Univariate
Odds Ratio
95% Confidence
Interval P Value
Age >10 years at HCT 1.13 0.28-4.48 .867
Male sex (versus female) 0.76 0.21-2.77 .675
T cell depletion 0.22 0.06-0.89 .033
HLA-identical sibling
(versus alternative donor)
7.03 1.70-29.14 .007
Time from HCT to
MCV4 vaccination
0.5-1 year 1.00
1-2 years 0.43 0.03-6.41 .539
>2 years 1.88 0.17-20.61 .607
History of chronic GVHD 1.39 0.34-5.76 .651
No significant univarate predictors were detected for serogroups A, Y,
and W (data not shown).
148 Biol Blood Marrow Transplant 18:141-155, 2012M. B. Mahler et al.of 16), and 69% (11/16) of patients, respectively, after
their second MCV4 vaccination. Figure 1 shows the
geometric mean titer after 1 immunization (n 5 46)
or 2 immunizations (n 5 16) with MCV4.DISCUSSION
Meningococcal disease is a rapidly progressive,
often devastating infection even with prompt diagnosis
and treatment [1-3]. In 2005, the ACIP recommended
a single dose of MCV4 in children ages 11-12 and
vaccination of adolescents entering high school if
not previously vaccinated, as well as those entering
college or considered at high risk for meningococcalFigure 1. Geometric mean concentration (GMC, micrograms/mL) and
95% confidence levels of antibodies against meningococcal serogroups
A, C, Y, and W-135 before and after immunization with MCV4.disease [3]. In 2007, the ACIP revised its recommenda-
tion to include routine immunization of all children
and adolescents ages 11-18 with MCV4 at the earliest
opportunity as well as immunization of individuals
ages 19-55 who are at increased risk for meningococcal
disease [14]. This latter group includes military re-
cruits, travelers to endemic areas (eg, as sub-Saharan
Africa), patients with functional or anatomic asplenia,
and those with congenital or acquired complement
deficiency [1-4,14]. Although .80% of otherwise
healthy adolescents develop a $4-fold rise in titer
to each of the 4 vaccine serogroups when measured
at 4 weeks after immunization [3], data on the
duration of protection in healthy individuals are
limited. A recent study [15] evaluated the duration of
protection in healthy adolescents after a single
vaccination with Menactra (MCV4) versus Menveo
(MenACWY-CRM; Novartis, Cambridge, MA),
a conjugated quadrivalent meningococcal vaccine li-
censed in the United States in 2010 [16]. This study
demonstrated that although the initial response was
comparable in recipients of either vaccine, a higher
proportion of individuals who received MenACWY-
CRM had a protective human serum bacterial anti-
body level .1:8 evaluated at 22 months after vaccina-
tion. Citing concerns regarding loss of protection, the
ACIP currently recommends initial vaccination of all
children at age 11-12, followed by a booster at age
15-16 [17].
Data on how best to protect allo-HCT recipients
against meningococcal disease are limited. Parkkali
et al. [8] evaluated the response of 44 adult recipients
of HLA-matched sibling bone marrow to a pure
polysaccharide meningococcal vaccine containing
serogroups A and C. Patients were vaccinated either
early (8 months; n 5 22) or later (22 months; n 5 20)
post-HCT. Antibody titers measured by enzyme
immunoassay at 1 month after immunization demon-
strated a $2-fold increase in titers against serogroup
A in 52% of the early group and 74% of the late group,
and against serogroup C in 76% of the early group and
89% of the late group. Despite the initial good
response, antibody titers decreased by 50%whenmea-
sured 6 months postimmunization.
The present study is the first to evaluate response to
the MCV4 vaccine after allo-HCT. It demonstrates
a poor response after a single vaccination in this patient
population, with 52% of patients having either no
response (n 5 16) or a response to only 1 antigen
(n 5 8), generally type A, an uncommon cause of
disease in the United States, although common in
sub-Saharan Africa and the Middle East. Response to
serogroup C, a common cause of meningococcal dis-
ease worldwide, was particularly poor. This limited im-
munogenicity of MCV4 was seen despite a median
time to immunization of 2.34 years post-HCT, sug-
gesting a lack of appropriate T and B cell populations
Biol Blood Marrow Transplant 18:141-155, 2012 149Meningococcal Vaccination After Transplantationnecessary for response at the time of immunization. Re-
sponse was significantly better after a booster vaccine,
with 13 of 16 patients responding to at least 3 se-
rogroups.
Current posttransplantation vaccination guide-
lines do not recommend routine measurement of pre-
vaccine and postvaccine titers. Nevertheless, for
HCT survivors entering college or the military or
traveling to countries where Neisseria meningitis is
prevalent or endemic, our findings suggest that docu-
mentation of response is prudent. This is particularly
true in recipients of posttransplantation rituximab,
who, even with recovery of B cells, did not respond
to this vaccine despite vaccination .1.5 years after
this therapy. This study suggests that allo-HCT re-
cipients would benefit from a 2-dose primary series
administered 2 months apart as recommended by
the ACIP in 2010 in patients with asplenia, HIV in-
fection, or complement deficiency [17]. Larger pro-
spective studies comparing the response and
duration of response of the 2 conjugated meningo-
coccal vaccines are warranted in allo-HCT and autol-
ogous HCT survivors.ACKNOWLEDGMENTS
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